About: The rationale for a multi-step therapeutic approach based on antivirals, drugs and nutrients with immunomodulatory activity in patients with coronavirus-SARS2-induced disease of different severities

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The rationale for a multi-step therapeutic approach based on antivirals, drugs and nutrients with immunomodulatory activity in patients with coronavirus-SARS2-induced disease of different severities Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The rationale for a multi-step therapeutic approach based on antivirals, drugs and nutrients with immunomodulatory activity in patients with coronavirus-SARS2-induced disease of different severities
Creator	Leandri, Paolo Corazza, Ivan De Biase, Dario Fiorino, Sirio Gallo, Claudio Giampieri, Enrico Manfredi, Roberto Rasciti, Edoardo Rasciti, Leonardo Sabbatani, Sergio Sifo, Debora Zippi, Maddalena
Source	Medline; PMC
abstract	In December 2019, a novel human-infecting coronavirus, named Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2), was recognised to cause a pneumonia epidemic outbreak with different degrees of severity in Wuhan, Hubei Province in China. Since then, this epidemic has spread worldwide; in Europe, Italy has been involved. Effective preventive and therapeutic strategies are absolutely required to block this serious public health concern. Unfortunately, few studies about SARS-CoV-2 concerning its immunopathogenesis and treatment are available. On the basis of the assumption that the SARS-CoV-2 is genetically related to SARS-CoV (about 82 % of genome homology) and that its characteristics, like the modality of transmission or the type of the immune response it may stimulate, are still poorly known, a literature search was performed to identify the reports assessing these elements in patients with SARS-CoV-induced infection. Therefore, we have analysed: (1) the structure of SARS-CoV-2 and SARS-CoV; (2) the clinical signs and symptoms and pathogenic mechanisms observed during the development of acute respiratory syndrome and the cytokine release syndrome; (3) the modification of the cell microRNome and of the immune response in patients with SARS infection; and (4) the possible role of some fat-soluble compounds (such as vitamins A, D and E) in modulating directly or indirectly the replication ability of SARS-CoV-2 and host immune response.
has issue date	2020-07-24(xsd:dateTime)
bibo:doi	10.1017/s0007114520002913
bibo:pmid	32703328
has license	no-cc
sha1sum (hex)	6b16f21b992bef55602e9cbd4933cf5e3728a398
schema:url	https://doi.org/10.1017/s0007114520002913
resource representing a document's title	The rationale for a multi-step therapeutic approach based on antivirals, drugs and nutrients with immunomodulatory activity in patients with coronavirus-SARS2-induced disease of different severities
has PubMed Central identifier	PMC7431858
has PubMed identifier	32703328
schema:publication	The British journal of nutrition
resource representing a document's body	covid:6b16f21b992bef55602e9cbd4933cf5e3728a398#body_text
is schema:about of	named entity 'pneumonia' named entity 'SARS-CoV' named entity 'replication' named entity 'genome' named entity 'outbreak' named entity 'drugs' named entity 'WORLDWIDE' named entity 'THERAPEUTIC' named entity 'PATIENTS' named entity 'ABOUT' named entity 'NAMED' named entity 'OBSERVED' named entity 'IMMUNE RESPONSE' named entity 'POORLY' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity '282' named entity 'STRATEGIES' named entity 'PATHOGENIC' named entity 'STRUCTURE' named entity 'SARS-CoV' named entity 'preventive' named entity 'fat-soluble' named entity 'Virus' named entity 'therapeutic' named entity 'acute' named entity 'block' named entity 'mechanisms' named entity 'coronavirus' named entity 'therapeutic strategies' named entity 'vitamins' named entity 'immunopathogenesis' named entity 'cytokine release syndrome' named entity 'Wuhan' named entity 'SARS-CoV' named entity 'SARS-CoV-2' named entity 'immune response' named entity 'immune response' named entity 'Corona Virus' named entity 'coronavirus' named entity 'therapeutic approach' named entity 'multi-step' named entity 'SARS2' named entity 'structure' named entity 'cytoplasm' named entity 'viruses' named entity 'cyclo-oxygenase' named entity 'SARS-CoV-2' named entity 'lungs' named entity 'sore throat' named entity 'hypoxaemia' named entity 'trachea' named entity 'isoprenoid' named entity 'negative-sense RNA' named entity 'genome' named entity 'mucosa-associated lymphoid tissue' named entity 'infection' named entity 'viral proteins' named entity 'viral infections' named entity 'human coronaviruses' named entity 'calcitriol' named entity 'bioinformatics' named entity 'HBV' named entity 'RARβ' named entity 'antioxidant' named entity 'protein-protein interactions' named entity 'alveolar' named entity 'cell differentiation' named entity 'lymphoid tissues' named entity 'infection' named entity 'Tocilizumab'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software